Top Premarket Decliners
8:00AM ET 8/17/2022 MT NewswiresIterum Therapeutics (ITRM) shares slumped 18% after the company said it will implement a 1-for-15 reverse stock split. Artelo Biosciences (ARTL) shares...
Top Midday Gainers
1:34PM ET 8/16/2022 MT NewswiresGreenBox POS (GBOX) late on Monday reported Q2 sales above market expectations. On Tuesday, GreenBox said it named J. Drew Byelick as its chief financial...
--HC Wainwright Lowers Price Target for Artelo Biosciences to $55 From $60, Maintains Buy Rating
10:18AM ET 8/12/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Artelo Biosciences Enrolls First Three Cohorts in Cancer-Related Anorexia, Weight-Loss Study
10:38AM ET 7/19/2022 MT NewswiresArtelo Biosciences (ARTL) said Tuesday it has completed enrollment of the first three cohorts in a study evaluating ART27.13 to treat cancer-related...
Artelo Says ART27.13 Shows Positive Pre-Clinical Results in Protecting Muscles From Cancer-Linked Degeneration; Shares Surge
9:32AM ET 4/13/2022 MT NewswiresArtelo Biosciences (ARTL) said Wednesday its candidate drug ART27.13 showed "promising pre-clinical results" in protecting human muscle cells from...
Artelo Biosciences, Trinity College Dublin Agree to Expand Partnership
10:53AM ET 3/28/2022 MT NewswiresArtelo Biosciences (ARTL) said Monday it agreed to expand its partnership with Trinity College Dublin with a focus on investigating the cellular biology of...
Artelo Biosciences Receives Patent Covering Means for Treating Medical Conditions Using Cannabidiol Cocrystal Composition
10:34AM ET 3/02/2022 MT NewswiresArtelo Biosciences (ARTL) said Wednesday the US Patent and Trademark Office issued a notice of allowance for a patent application pertaining to ART12.11, a...
Artelo Biosciences' Lead Cannabinoid No Longer Schedule 1 Controlled Substance in UK; Shares Rise Pre-Bell
9:30AM ET 1/11/2022 MT NewswiresArtelo Biosciences (ARTL) reported that the UK government no longer considers the company's lead clinical cannabinoid ART27.13 a Schedule 1 controlled...